These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 33684562)
1. Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis. Court R; Centner CM; Chirehwa M; Wiesner L; Denti P; de Vries N; Harding J; Gumbo T; Maartens G; McIlleron H Int J Infect Dis; 2021 Apr; 105():688-694. PubMed ID: 33684562 [TBL] [Abstract][Full Text] [Related]
2. Steady-state population pharmacokinetics of terizidone and its metabolite cycloserine in patients with drug-resistant tuberculosis. Mulubwa M; Mugabo P Br J Clin Pharmacol; 2019 Sep; 85(9):1946-1956. PubMed ID: 31046167 [TBL] [Abstract][Full Text] [Related]
3. [Rezonizat and cycloserine in complex therapy of drug resistant tuberculosis (comparative studies)]. Sokolova GB; Lazareva IaR; Kirtaeva OV; Romanova EV; Tsybane AA Antibiot Khimioter; 2008; 53(11-12):25-8. PubMed ID: 19441654 [TBL] [Abstract][Full Text] [Related]
4. Steady state pharmacokinetics of cycloserine in patients on terizidone for multidrug-resistant tuberculosis. Court R; Wiesner L; Stewart A; de Vries N; Harding J; Maartens G; Gumbo T; McIlleron H Int J Tuberc Lung Dis; 2018 Jan; 22(1):30-33. PubMed ID: 29297422 [TBL] [Abstract][Full Text] [Related]
5. Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis. Hwang TJ; Wares DF; Jafarov A; Jakubowiak W; Nunn P; Keshavjee S Int J Tuberc Lung Dis; 2013 Oct; 17(10):1257-66. PubMed ID: 23735593 [TBL] [Abstract][Full Text] [Related]
6. Treatment Outcomes and Adverse Drug Effects of Ethambutol, Cycloserine, and Terizidone for the Treatment of Multidrug-Resistant Tuberculosis in South Africa. van der Walt ML; Shean K; Becker P; Keddy KH; Lancaster J Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33046491 [TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with Terizidone. Chirehwa MT; Court R; de Kock M; Wiesner L; de Vries N; Harding J; Gumbo T; Maartens G; Warren R; Denti P; McIlleron H Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32816738 [TBL] [Abstract][Full Text] [Related]
8. Psychiatric issues in the management of patients with multidrug-resistant tuberculosis. Vega P; Sweetland A; Acha J; Castillo H; Guerra D; Smith Fawzi MC; Shin S Int J Tuberc Lung Dis; 2004 Jun; 8(6):749-59. PubMed ID: 15182146 [TBL] [Abstract][Full Text] [Related]
9. Serious treatment related adverse drug reactions amongst anti-retroviral naïve MDR-TB patients. Van der Walt M; Lancaster J; Odendaal R; Davis JG; Shean K; Farley J PLoS One; 2013; 8(4):e58817. PubMed ID: 23573193 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic Modeling, Simulation, and Development of a Limited Sampling Strategy of Cycloserine in Patients with Multidrug-/Extensively Drug-Resistant Tuberculosis. van der Galiën R; Boveneind-Vrubleuskaya NV; Peloquin C; Skrahina A; Touw DJ; Alffenaar JC Clin Pharmacokinet; 2020 Jul; 59(7):899-910. PubMed ID: 31981103 [TBL] [Abstract][Full Text] [Related]
11. Amount of Cycloserine Emanating from Terizidone Metabolism and Relationship with Hepatic Function in Patients with Drug-Resistant Tuberculosis. Mulubwa M; Mugabo P Drugs R D; 2019 Sep; 19(3):289-296. PubMed ID: 31396892 [TBL] [Abstract][Full Text] [Related]
12. Cycloserine induced psychosis with hepatic dysfunction. Tandon VR; Rani N; Roshi ; Gupta R; Arora M; Khajuria V; Mahajan V Indian J Pharmacol; 2015; 47(2):230-1. PubMed ID: 25878391 [TBL] [Abstract][Full Text] [Related]
13. Cycloserine-induced psychosis in a young female with drug-resistant tuberculosis. Sharma B; Handa R; Nagpal K; Prakash S; Gupta PK; Agrawal R Gen Hosp Psychiatry; 2014; 36(4):451.e3-4. PubMed ID: 24766906 [TBL] [Abstract][Full Text] [Related]
14. Optimizing dosing of the cycloserine pro-drug terizidone in children with rifampicin-resistant tuberculosis. van der Laan LE; Garcia-Prats AJ; McIlleron H; Abdelwahab MT; Winckler JL; Draper HR; Wiesner L; Schaaf HS; Hesseling AC; Denti P Antimicrob Agents Chemother; 2023 Dec; 67(12):e0061123. PubMed ID: 37971239 [TBL] [Abstract][Full Text] [Related]
15. [Russian cycloserine in complex therapy of drug resistant tuberculosis]. Sokolova GB; Kirtaeva OV; Lazareva IaV; Tsybanev AA Antibiot Khimioter; 2008; 53(5-6):32-4. PubMed ID: 19069180 [No Abstract] [Full Text] [Related]
16. Neuropsychiatric reactions induced by cycloserine in the treatment of multidrug-resistant tuberculosis: what an Indian female patient tells us. Intini E; Kishore G; Richeldi L; Udwadia ZF BMJ Case Rep; 2019 Dec; 12(12):. PubMed ID: 31806629 [TBL] [Abstract][Full Text] [Related]
17. A patient of multidrug-resistant tuberculosis on category IV treatment regimen presenting with psychosis. Sarkar S; Sood M Natl Med J India; 2011; 24(4):244-5. PubMed ID: 22208150 [No Abstract] [Full Text] [Related]
18. Prevalence and incidence of symmetrical symptomatic peripheral neuropathy in patients with multidrug-resistant TB. Conradie F; Mabiletsa T; Sefoka M; Mabaso S; Louw R; Evans D; Van Rie A S Afr Med J; 2013 Oct; 104(1):24-6. PubMed ID: 24388081 [TBL] [Abstract][Full Text] [Related]
19. Neuroleptic malignant syndrome in cycloserine-induced psychosis. Sawant NS; Kate NS; Bhatankar SS; Kulkarni PS Indian J Pharmacol; 2015; 47(3):328-9. PubMed ID: 26069374 [TBL] [Abstract][Full Text] [Related]
20. [A case of multi-drug resistant tuberculosis showing psychiatric adverse effect by cycloserine]. Fujita J; Sunada K; Hayashi H; Hayashihara K; Saito T Kekkaku; 2008 Jan; 83(1):21-5. PubMed ID: 18283911 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]